α-Chymotrypsin regulates free fatty acids and UCHL-1 to ameliorate N-methyl nitrosourea induced mammary gland carcinoma in albino wistar rats
Abstract This study was undertaken to investigate the effect of α-chymotrypsin on methyl nitrosourea (MNU) induced mammary gland carcinoma in albino wistar rats. Animals were randomized into four groups (six animals in each). Group I (sham control 0.9 % normal saline p.o.); Group II (toxic control, MNU 47 mg/kg, i.v.); Group III (α-chymotrypsin, 5 mg/kg, p.o.); Group IV (α-chymotrypsin, 10 mg/kg p.o.). Toxicity was induced by single i.v. injection of MNU followed by α-chymotrypsin supplementation therapy for 100 days. MNU treatment was evident with increased alveolar bud count, differentiation score, upregulated inflammatory enzymes markers (COX, LOX and NO) antioxidative stress markers (TBARs, SOD, catalase and GSH).MNU associated toxicity was also ascertained by PGP 9.5 and NF-κB expression in the mammary gland tissue followed by FAME analysis for fatty acid profiling. α-chymotrypsin afforded significant protection against the deleterious effects of MNU..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Inflammopharmacology - 24(2016), 5 vom: 26. Sept., Seite 277-286 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rani, Asha [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
α-Chymotrypsin |
| Anmerkungen: |
© Springer International Publishing 2016 |
|---|
| doi: |
10.1007/s10787-016-0280-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2034459539 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2034459539 | ||
| 003 | DE-627 | ||
| 005 | 20230513052453.0 | ||
| 007 | tu | ||
| 008 | 200819s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10787-016-0280-5 |2 doi | |
| 035 | |a (DE-627)OLC2034459539 | ||
| 035 | |a (DE-He213)s10787-016-0280-5-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Rani, Asha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a α-Chymotrypsin regulates free fatty acids and UCHL-1 to ameliorate N-methyl nitrosourea induced mammary gland carcinoma in albino wistar rats |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer International Publishing 2016 | ||
| 520 | |a Abstract This study was undertaken to investigate the effect of α-chymotrypsin on methyl nitrosourea (MNU) induced mammary gland carcinoma in albino wistar rats. Animals were randomized into four groups (six animals in each). Group I (sham control 0.9 % normal saline p.o.); Group II (toxic control, MNU 47 mg/kg, i.v.); Group III (α-chymotrypsin, 5 mg/kg, p.o.); Group IV (α-chymotrypsin, 10 mg/kg p.o.). Toxicity was induced by single i.v. injection of MNU followed by α-chymotrypsin supplementation therapy for 100 days. MNU treatment was evident with increased alveolar bud count, differentiation score, upregulated inflammatory enzymes markers (COX, LOX and NO) antioxidative stress markers (TBARs, SOD, catalase and GSH).MNU associated toxicity was also ascertained by PGP 9.5 and NF-κB expression in the mammary gland tissue followed by FAME analysis for fatty acid profiling. α-chymotrypsin afforded significant protection against the deleterious effects of MNU. | ||
| 650 | 4 | |a α-Chymotrypsin | |
| 650 | 4 | |a Mammary gland | |
| 650 | 4 | |a PGP 9.5 | |
| 650 | 4 | |a Oxidative stress | |
| 650 | 4 | |a NF-κB p65 | |
| 650 | 4 | |a FAME | |
| 700 | 1 | |a Roy, Subhadeep |4 aut | |
| 700 | 1 | |a Singh, Manjari |4 aut | |
| 700 | 1 | |a Devi, Uma |4 aut | |
| 700 | 1 | |a Yadav, Rajnish K. |4 aut | |
| 700 | 1 | |a Gautam, Swetlana |4 aut | |
| 700 | 1 | |a Rawat, Jitendra K. |4 aut | |
| 700 | 1 | |a Ansari, Mohd. Nazam |4 aut | |
| 700 | 1 | |a Saeedan, Abdulaziz S. |4 aut | |
| 700 | 1 | |a Prakash, Anand |4 aut | |
| 700 | 1 | |a Kaithwas, Gaurav |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d Springer International Publishing, 1991 |g 24(2016), 5 vom: 26. Sept., Seite 277-286 |w (DE-627)170602893 |w (DE-600)1080058-X |w (DE-576)505034115 |x 0925-4692 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2016 |g number:5 |g day:26 |g month:09 |g pages:277-286 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10787-016-0280-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4277 | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 24 |j 2016 |e 5 |b 26 |c 09 |h 277-286 | ||